Skip to main content

InflaRx N.V.

IFRX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001708688

No open-market purchases or sales by InflaRx N.V. insiders were filed in the last 90 days; 62 institutions reported holding it in 13F filings for Q2 2026, worth $218.1M in total; no superinvestor holds it.

Key figures

Insider buysOpen market, last 90 days
0
Insider sellsOpen market, last 90 days
0
13F holdersQ2 2026, +27 vs. previous quarter
62
13F valueReported value at the end of Q2 2026
$218.1M
Superinvestors holdingAt the end of Q2 2026
0

Price chart

Superinvestors holding IFRX, Q2 2026

Go to the superinvestors tab

No superinvestor reported holding IFRX at the end of Q2 2026.

Latest insider trades

Open-market purchases and sales by InflaRx N.V. insiders from Form 4, newest first.

See all insider trades

No open-market purchases or sales by InflaRx N.V. insiders are on file.

Top 10 13F holders, Q2 2026

The largest institutional positions in InflaRx N.V. at the end of Q2 2026; share changes are against Q1 2026.

See all 62 holders
Institutions holding IFRX in Q2 2026
InstitutionSharesValue% of portfolioChange in sharesAction
Suvretta Capital Management, LLC22,933,910$51.4M1.08%+15,000,000+189.1%Added
TCG Crossover Management, LLC14,500,000$32.5M0.78%+14,500,000New
FMR LLC8,163,341$18.3M0.00%+8,163,341New
Commodore Capital LP7,300,000$16.4M0.97%+7,300,000New
Kalehua Capital Management LLC5,795,538$13.0M4.14%+5,795,538New
Spruce Street Capital LP5,352,198$12.0M2.35%+5,352,198New
683 Capital Management, LLC5,065,000$11.3M1.04%+1,750,000+52.8%Added
Farallon Capital Management, L.L.C.3,325,000$7.45M0.04%+3,325,000New
StemPoint Capital LP3,228,255$7.23M1.25%+3,228,255New
Great Point Partners LLC3,046,557$6.82M1.61%+3,046,557New